31 studies found for:    " November 11, 2009":" December 11, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Completed Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers
Condition: Human Immunodeficiency Virus
Intervention: Drug: Raltegravir
22 Suspended Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
Conditions: AIDS-related Kaposi Sarcoma;   HIV Infection;   Recurrent Kaposi Sarcoma
Interventions: Drug: bortezomib;   Other: laboratory biomarker analysis
23 Completed Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Condition: HIV Infections
Intervention:
24 Completed
Has Results
Trichomonas Vaginalis Recurrence Among HIV+ Women
Conditions: Trichomonas Infections;   HIV Infections
Intervention: Drug: Metronidazole
25 Completed Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients
Condition: HIV-1 Infection
Interventions: Drug: ART Intensification;   Biological: Immunomodulation
26 Unknown  Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients
Conditions: HIV-1 Infection;   Cancer;   Immunosuppression
Intervention: Other: serologic testing
27 Completed S.T.A.R.S.: Sistas Talking About Real Solutions
Condition: HIV Prevention
Interventions: Behavioral: STARS: Sistas Talking About Real Solutions;   Behavioral: General Health & Nutrition
28 Unknown  Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients
Conditions: HIV-1 Adults Patients;   AIDS;   Triple Class Failure
Interventions: Drug: maraviroc;   Drug: Raltegravir;   Drug: Darunavir/ritonavir
29 Recruiting Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Condition: Infections, Papillomavirus
Interventions: Biological: GSK Biologicals' HPV vaccine 580299;   Biological: Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)
30 Active, not recruiting Safety and Immunogenicity of MVA.HIVconsv in HIV-1 Seropositive Adults on HAART
Condition: HIV-1
Interventions: Biological: MVA.HIVconsv low dose;   Other: Placebo low dose;   Biological: MVA.HIVconsv high dose;   Other: Placebo high dose
31 Completed Observational Study of the Preventive Trial With HIV-1 Tat Protein
Condition: Healthy Subjects
Intervention:

Show previous page of results Previous Page (1-20) Studies Shown (21-31) Next Page
Indicates status has not been verified in more than two years